Results 51 to 60 of about 1,005 (173)

Sleep Reactivity Amplifies the Impact of Pre‐Sleep Cognitive Arousal on Sleep Disturbances

open access: yesJournal of Sleep Research, Volume 35, Issue 3, June 2026.
This study investigates how sleep reactivity moderates the ‘stress‐pre‐sleep arousal‐sleep’ pathway in university students. At the within‐individual level, both high and low sleep‐reactive groups showed increased pre‐sleep cognitive arousal and sleep disruptions in response to elevated daily stress.
Noof Abdullah Saad Shaif   +5 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

open access: yesActa Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian   +3 more
wiley   +1 more source

Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial

open access: yes, 2023
BACKGROUND: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for ...
Lehert, P   +10 more
core   +2 more sources

Supply and Demand in the Mathematics of Rare Disease Drug Development: Why Choosing the Right Model Is Crucial

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clinical trials for rare diseases face a fundamental mathematical challenge that conventional randomized controlled trial (RCT) designs cannot overcome. With approximately 95% of the estimated 10,000–16,000 rare diseases lacking approved therapies, and drug development programs failing at rates exceeding 75% in non‐oncology indications, the ...
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease

open access: yesMovement Disorders, Volume 41, Issue 4, Page 1004-1015, April 2026.
Abstract Background Parkinson's disease (PD) is associated with several behavioral and cognitive symptoms, the neurobiological background of which is not yet fully understood. Objectives The aim was to investigate the association between monoamine function and four specific nonmotor symptoms in early PD using the Parkinson's Progression Markers ...
Kalle J. Niemi   +3 more
wiley   +1 more source

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies [PDF]

open access: yes, 2017
Background and purpose: We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant. Experimental approach: Nonclinical studies envisaged both in the ICH S7B guideline and Comprehensive in vitro ...
Laurent Landais   +22 more
core   +1 more source

Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract Neuromodulatory subcortical systems (NSSs) are uniquely susceptible to dementia‐related pathology, leading to frequent molecular and behavioral impairments associated with altered function of these nuclei. Some of these systems display clear sex‐specific cytoarchitecture and signaling leading to distinct physiology and behavioral outputs in ...
Rosaria J. Rae   +53 more
wiley   +1 more source

Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial

open access: yes, 2013
Background: Narcolepsy is characterised by excessive daytime sleepiness (EDS) and cataplexy. Histamine neurons are crucial to maintain wakefulness. We assessed the safety and efficacy of pitolisant (previously called BF2.649), a selective histamine H3 ...
Bassetti, Claudio   +20 more
core   +1 more source

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials

open access: yes, 2021
International audienceBackground: Pitolisant is approved in the USA and Europe for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.Objective: Analyses evaluated the time to onset of clinical response during treatment ...
Watson, Nathaniel   +6 more
core   +1 more source

Activity‐restoring mutations in the histamine H3 receptor increase constitutive activity and reduce structural stability

open access: yesProtein Science, Volume 35, Issue 1, January 2026.
Abstract The histamine H3 receptor (H3R) is a class A G protein‐coupled receptor (GPCR) that regulates neurotransmitter release in the central nervous system. Although structures of H3R in both inactive and active states have been elucidated, the functional roles of specific residues remain unclear.
Ami Nakajima   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy